AstraZeneca PLC (AZN)
After hours:
| Previous close | 76.62 |
| Open | 76.13 |
| Bid | 76.05 x 500 |
| Ask | 76.12 x 500 |
| Day's range | 75.79 - 76.51 |
| 52-week range | 60.47 - 79.36 |
| Volume | |
| Avg. volume | 5,255,821 |
| Market cap | 240.281B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 37.66 |
| EPS (TTM) | 2.02 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | 1.45 (1.89%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 83.11 |
ZacksAstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
GlobeNewswireCellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and g
ZacksHere's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
